The Global Men’s Health Market is Forecast to Show Moderate Growth during the Forecast Period

Monday 20 February 2012, Amsterdam

The report provides in-depth analysis on the drivers and barriers that affect the global men’s health therapeutics market. The report analyzes the markets for men’s health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, market revenue, and the annual cost of treatment (ACT) are forecast until 2017 for the key geographies, as well as for the leading therapeutic segments. Furthermore, the report provides profiles of the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

They indicates that the global men’s health therapeutics market has been one of the fastest growing markets in the pharmaceutical industry. However, the market growth is expected to slow down in the future due to various restraints such as the expiry of the patents of key drugs, and a low treatment seeking and diagnosis rate. Nevertheless, the global men’s health therapeutics market is still forecast to grow at a moderate rate in the future.

The Global Men’s Health Market is Forecast to Show Moderate Growth during the Forecast Period

See figure: Men’s Health Therapeutics Market to 2017, Global, Revenue Forecasts ,$m, 2002-2017

In 2010, the global men’s health market was estimated to be worth $9,162m, representing a Compound Annual Growth Rate (CAGR) of 8.4% between 2002 and 2010. By 2017, the global men’s health market is estimated to reach $12,163m, indicating a CAGR of 4.1% between 2010 and 2017. The major reason for the reduced growth rate is the first patent expiry of the blockbuster drug, Viagra (sildenafil citrate) in 2012. The drug contributes significantly to the entire men’s health market, and accounts for more than 55% of the market’s revenue. As a result, the patent expiry of this drug will directly affect the market’s growth.

The men’s health pipeline portfolio comprises both me-too and first-in-class molecules in the late stage of development. These molecules are expected to be launched during the forecast period. Some of these pipeline candidates offer improved therapeutic outcomes and a better safety profile compared to current market products. If launched, these drugs will offer physicians and patients better treatment options. This will boost the market growth.

In addition, a steady increase in the diseased population and in the treated population will sustain modest market growth during the forecast period.

Men’s Health Pipeline Portfolio is Dominated by Late-stage Pipeline Candidates

The men’s health pipeline portfolio has 64 molecules across different developmental stages. The number of pipeline candidates in the regulatory filing, Phase III and Phase II stages of development accounted for approximately 68% of the total number of pipeline molecules. In addition, the pipelines of two major markets, erectile dysfunction (ED) and Benign Prostatic Hyperplasia (BPH) constitute approximately 69% of the total men’s health pipeline. This indicates that the launch of the key late stage pipeline molecules will boost the ED and BPH markets in particular.

The ED pipeline consists of me-too molecules in Phase III such as alfuzosin and Zydena (udenafi). These drugs are phosphodiesterase type 5 inhibitors and expected to be launched in the near future. Moreover, New Drug Application (NDA) filed molecules such as avanafil and Vitaros (alprostadil) are first-in-class molecules. The launch of these molecules will support the market growth.

The male hypogonadism market has two molecules in the regulatory filing stage. These molecules offer some benefits over the current market products. The BPH market consists of eight molecules in Phase III and one molecule in the regulatory filing stage. The launch of these molecules will sustain the market growth during the forecast period. The PE market does not have any current FDA approved products in major geographies. The market is primarily dominated by off-label drugs. However the introduction of late stage pipeline drugs in the market will significantly boost the market growth.

Major Strategic Consolidations have Driven the Men’s Health Market

Between 2004 and 2010, the men’s health therapeutic sector witnessed numerous strategic consolidations. With about 93 strategic consolidations, the men’s health therapeutics sector was on a significant growth path during 2004-2010. There have been increasing numbers of licensing agreements for drugs in the approval stages. Geographically, the emerging nations are seen as regions with strong market opportunity and therefore the number of licensing agreements in these nations is expected to increase. Major licensing agreements in 2010 included Eli Lilly’s licensing agreement with Acrux for the commercialization of Axiron (testosterone topical solution); a merger agreement between Biovail Corp. and Valeant Pharmaceuticals; and the acquisition of ICOS by Eli Lilly in 2007 collectively accounted for approximately $6,995m in terms of deal value. These have strengthened the financial stability of the men’s health market players.

Most of the licensing agreements were focused on co-promotion, distribution, adding a new product to their existing portfolio, marketing, and receiving full marketing rights for the original product. The US accounted for more than 50% of strategic consolidation activities. Analysis suggests that most of the pharmaceutical companies find it beneficial to license a drug in the approval stage.